Product Name
TRIP11, siRNA
Full Product Name
TRIP11 siRNA (Human)
Product Synonym Names
CEV14; Thyroid receptor-interacting protein 11; TR-interacting protein 11; TRIP-11; Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; GMAP-210; Trip230
Product Gene Name
TRIP11 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q15643
Specificity
TRIP11 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human TRIP11 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of TRIP11 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
TRIP11 sirna
siRNA to inhibit TRIP11 expression using RNA interference
Applications Tested/Suitable for TRIP11 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for TRIP11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_004230.2
[Other Products]
NCBI GenBank Nucleotide #
NM_004239.3
[Other Products]
UniProt Primary Accession #
Q15643
[Other Products]
UniProt Secondary Accession #
O14689; O15154; O95949; B2RUT2[Other Products]
UniProt Related Accession #
Q15643[Other Products]
Molecular Weight
227,586 Da
NCBI Official Full Name
thyroid receptor-interacting protein 11
NCBI Official Synonym Full Names
thyroid hormone receptor interactor 11
NCBI Official Symbol
TRIP11 [Similar Products]
NCBI Official Synonym Symbols
ACG1A; CEV14; GMAP210; TRIP-11; TRIP230; GMAP-210
[Similar Products]
NCBI Protein Information
thyroid receptor-interacting protein 11
UniProt Protein Name
Thyroid receptor-interacting protein 11
UniProt Synonym Protein Names
Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; GMAP-210; Trip230
Protein Family
Thyroid receptor-interacting protein
UniProt Gene Name
TRIP11 [Similar Products]
UniProt Synonym Gene Names
CEV14; TR-interacting protein 11; TRIP-11; GMAP-210 [Similar Products]
UniProt Entry Name
TRIPB_HUMAN
NCBI Summary for TRIP11
This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.[provided by RefSeq, Mar 2010]
UniProt Comments for TRIP11
TRIP11: Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB- modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure. A chromosomal aberration involving TRIP11 may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with PDGFRB. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia. Defects in TRIP11 are the cause of achondrogenesis type 1A (ACG1A). A form of achondrogenesis type 1, a lethal form of chondrodysplasia characterized by deficient ossification in the lumbar vertebrae and absent ossification in the sacral, pubic and ischial bones and clinically by stillbirth or early death. In addition to severe micromelia, there is a disproportionately large cranium due to marked edema of soft tissues.
Protein type: Nuclear receptor co-regulator; Transcription, coactivator/corepressor
Chromosomal Location of Human Ortholog: 14q31-q32
Cellular Component: Golgi membrane; Golgi apparatus; inner acrosomal membrane; cytoskeleton; cis-Golgi network; nucleus
Molecular Function: protein binding; transcription coactivator activity
Biological Process: transcription from RNA polymerase II promoter; organelle organization and biogenesis; protein targeting to Golgi
Disease: Achondrogenesis, Type Ia
Research Articles on TRIP11
1. Rb is present in HIF1alpha-ARNT/HIF1beta transcriptional complexes associated with TRIP230 as determined by co-immuno-precipitation, GST-pull-down and ChIP assays
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
